Acatisia: A Emergência Neurológica Escondida Atrás de "Inquietação"
Acatisia é um dos efeitos adversos mais perigosos e não reconhecidos de medicamentos psiquiátricos. O termo clínico traduz do grego como "incapacidade de sentar" — uma descrição tão inadequada que beira a negligência. O que os pacientes experimentam é um estado de tormento interior insuportável: uma agitação neurológica tão grave que muitos descrevem como o pior sofrimento que já experimentaram. Levou pessoas sem histórico psiquiátrico anterior a suicídio e violência. A pesquisa abaixo documenta o que o establishment médico foi lento em reconhecer: acatisia é uma emergência neurológica que ameaça a vida, não um efeito colateral leve.
Por Que Esta Seção Existe Separadamente
Acatisia merece sua própria seção de pesquisa porque é o único efeito adverso agudo mais perigoso de ISRSs, ISRSNs e antipsicóticos — e porque a palavra "inquietação" usada em informação de prescrição levou clínicos, pacientes e famílias a subestimar catastroficamente sua gravidade. Pessoas morreram porque acatisia não foi reconhecida pelo que é: um estado neurológico que pode fazer a morte parecer o único escape do sofrimento insuportável.
Citações Chave:
1 Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia
Rothschild AJ, Locke CA. J Clin Psychiatry. 1991;52(12):491-493.
Abstract: Landmark case series documenting three patients who made serious suicide attempts during fluoxetine (Prozac) treatment and developed severe akathisia upon retreatment. All three patients reported that akathisia had precipitated their prior suicide attempts — the unbearable inner restlessness and agitation made them feel that death was the only way to stop the suffering. Symptoms resolved completely with fluoxetine discontinuation or addition of propranolol. This study provided early, direct evidence that SSRI-induced akathisia can cause suicidality in patients who were not previously suicidal.
2 SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment
Lane RM. J Psychopharmacol. 1998;12(2):192-214.
Abstract: Comprehensive review by Roger Lane documenting that SSRIs can induce extrapyramidal side effects including akathisia through serotonergically-mediated inhibition of dopamine. The review identifies risk factors, demonstrates that akathisia is far more common with SSRIs than acknowledged in prescribing literature, and emphasizes the critical importance of early recognition. Lane documents that unrecognized akathisia leads to dose increases (worsening the condition), misdiagnosis as psychiatric deterioration, and treatment with additional medications that compound the neurological injury.
3 A case of suicidal and homicidal ideation and akathisia in a double-blind neuroleptic crossover study
Shaw ED, Mann JJ, Weiden PJ, et al. J Clin Psychopharmacol. 1986;6(3):196-197.
Abstract: Case report from a controlled research setting documenting the acute emergence of both suicidal and homicidal ideation temporally associated with akathisia during neuroleptic administration. Both the violent ideation and akathisia resolved completely when the offending drug was discontinued and akathisia was treated. This study, from a double-blind research environment, provides unusually strong causal evidence that akathisia can independently generate both suicidal and homicidal thoughts in patients who had neither before the drug was administered.
4 Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family
Lucire Y, Crotty C. Pharmacogenomics Pers Med. 2011;4:65-81.
Abstract: Forensic pharmacogenomics study of eight individuals who committed homicide while taking antidepressants, none of whom had prior histories of violence or serious mental illness. Genetic testing revealed that all had reduced-function CYP450 polymorphisms that, combined with enzyme-inhibiting medications, caused dangerously elevated antidepressant levels. The resulting akathisia was so severe that it drove catastrophic violent outcomes. This study demonstrates that genetic variation in drug metabolism can turn a standard prescription into a death sentence — and that akathisia is the mechanism through which the violence occurs.
5 The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia
Fleischhacker WW, et al. J Neuropsychiatry Clin Neurosci. 2000;13(3):336-342.
Abstract: Study demonstrating that akathisia severity was directly associated with higher suicidality scores, depersonalization, and agitation in patients taking antipsychotics. Depressive mood and the patient's subjective awareness of akathisia emerged as independent predictors of suicidal ideation. The findings indicate that akathisia is not merely uncomfortable — it creates a neurological state in which the experience of existing becomes so intolerable that self-destruction appears rational.
6 Neuroleptic-induced akathisia and violence: a review
Leong GB, Silva JA. J Forensic Sci. 2003;48(1):187-189.
Abstract: Forensic review examining the association between neuroleptic-induced akathisia and aggressive/violent behavior. The authors document that this association was not formally recognized until two and a half decades after antipsychotics were introduced — meaning that for 25 years, patients were being driven to violence by their medications while the medical profession failed to identify the cause. The review has significant forensic implications for cases of medication-induced violence.
7 Akathisia and violence
Van Putten T. J Clin Psychiatry. 1975.
Abstract: Foundational observational study reporting the association between akathisia and violent behavior in psychiatric settings. Van Putten documented that in approximately half of violent incidents, both victims and assailants were experiencing akathisia, while bystanders rarely were. This early epidemiological observation established akathisia as a direct precipitant of violence — not a correlate, but a cause — decades before this link was acknowledged in prescribing information.
8 Drug-induced akathisia, suicidal ideation, and its treatment in the elderly
Sachdev P, Lonergan G. Drugs Aging. 2001.
Abstract: Clinical documentation of drug-induced akathisia presenting with suicidal ideation in elderly patients on antipsychotic medications. The study demonstrates a direct relationship between increasing akathisia severity and the emergence and worsening of suicidal ideation and aggressive behavior. The elderly population is particularly vulnerable because akathisia is frequently misattributed to "agitation" or "confusion" and treated with additional medications that worsen the condition.
9 Akathisia, suicidality, and fluoxetine
Hamilton SH, Opler LA. J Clin Psychopharmacol. 1992.
Abstract: Proposed the syndrome of "Extrapyramidal-Induced Dysphoric Reactions" with suicidal ideation as an extreme manifestation. The authors demonstrated that increased serotonin activity from SSRIs can inhibit nigrostriatal dopamine pathways, inducing extrapyramidal side effects including akathisia with severe psychiatric consequences. This mechanistic work helped explain why a drug prescribed for depression could paradoxically create a neurological state more dangerous than the condition it was meant to treat.
Tratamento Opioide para Acatisia:
Importante: A terapia com opioides carrega seus próprios riscos significativos, incluindo dependência, vício, tolerância e depressão respiratória. Deve ser considerada apenas como último recurso quando todas as outras opções de tratamento foram esgotadas ou quando um paciente está em perigo imediato.
10 Evidence for underactivity of the opioid system in neuroleptic-induced akathisia
Gillman MA, Sandyk R, Lichtigfeld FJ. Psychiatry Research. 1984;13(2):187.
Abstract: Foundational study proposing that endogenous opioid system underactivity is involved in the pathogenesis of neuroleptic-induced akathisia. A patient with severe acute akathisia showed complete suppression of motor restlessness with opioid therapy, which was rapidly reversed by naloxone (an opioid receptor blocker). This early mechanistic work established that akathisia may be driven in part by opioid system dysfunction — opening the door to opioid-based treatment approaches.
11 Opioid responsiveness in patients with neuroleptic-induced akathisia
Walters AS, Hening WA, Chokroverty S. Movement Disorders. 1986;1(2):119-127.
Abstract: Five patients with acute or tardive neuroleptic-induced akathisia were videotaped before, during, and after opioid treatment (propoxyphene or codeine). Three blinded observers agreed that on opioids, all patients showed substantial to complete improvement of their stereotyped restless akathitic movements, while matching placebo was not beneficial. One patient who improved on opioids was challenged with naloxone and experienced a brief but severe reactivation of akathisia. The results suggest opioids offer a selective therapy for akathisia and further implicate the endogenous opioid system in its pathophysiology.
12 Opioids a better treatment for acute than tardive akathisia: possible role for the endogenous opiate system in neuroleptic-induced akathisia
Sandyk R. Medical Hypotheses. 1989;28(1):1-2.
Abstract: Building on prior clinical observations, this paper reports that opioids are more effective for acute akathisia than for tardive akathisia, suggesting that endogenous opioid system dysfunction plays a greater role in the acute phase. The finding has implications for early treatment: opioid intervention at the onset of akathisia may prevent the condition from progressing to the more treatment-resistant tardive form.
13 Restless legs syndrome, neuroleptic-induced akathisia, and opioid-withdrawal restlessness: shared neuronal mechanisms?
Walters AS, et al. Sleep. 2023;47(3):zsad273.
Abstract: Recent paper from Johns Hopkins proposing shared neuronal mechanisms between restless legs syndrome, neuroleptic-induced akathisia, and opioid-withdrawal restlessness. The authors identify a key role for specific striatal neurons expressing μ-opioid receptors (MORs) in mediating all three conditions. This work provides modern neuroanatomical and receptor-level evidence for why opioid agonists are effective in treating akathisia — the same neurons disrupted by neuroleptics are the ones rescued by opioid therapy.
The Cost of the Word "Restlessness"
Every prescribing information sheet for SSRIs, SNRIs, and antipsychotics lists akathisia as a potential side effect — using the word "restlessness." This single word has contributed to untold deaths. A patient told they might experience "restlessness" has no way of understanding that they could develop a neurological state so unbearable that suicide becomes a rational response to the suffering. A clinician who reads "restlessness" in a side effect profile has no reason to treat this as a life-threatening emergency requiring immediate intervention.
O studies above — spanning four decades of research — document that akathisia drives suicide, homicide, and self-harm through a direct neurological mechanism. It is not a psychological reaction. It is not anxiety. It is not the patient's underlying condition worsening. It is a drug-induced neurological emergency that the medical vocabulary has been systematically designed to minimize.
Benzodiazepines: Long-Term Neurological Consequences
Benzodiazepines, widely prescribed for anxiety and insomnia, cause lasting changes to brain chemistry and structure. Protracted withdrawal syndrome — more accurately described as benzodiazepine-induced neurological injury — affects a substantial proportion of long-term users, with symptoms persisting months or years after cessation.
Citações Chave:
7 Benzodiazepine use and cognitive decline in the elderly
Picton JD, Marino AB, et al. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2018. DOI: 10.2146/ajhp160381
Antipsychotics: Tardive Dyskinesia, Brain Volume Loss & Withdrawal
Antipsychotics cause lasting neurological damage through dopamine receptor antagonism, including potentially long-term movement disorders (tardive dyskinesia), measurable brain volume reduction, severe metabolic disruption, and a withdrawal syndrome that mimics relapse — trapping patients on medication indefinitely.
Citações Chave:
1 Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States
Carbon M, et al. PLoS ONE. 2017;12(4):e0175768.
Abstract: Cross-sectional study documenting tardive dyskinesia prevalence of 30.0% in patients on first-generation antipsychotics and 20.7% on second-generation antipsychotics, demonstrating that newer "atypical" agents carry substantial TD risk. Resolution rates remain low at approximately 13%, confirming that tardive dyskinesia is often long-term and persists in the majority of affected patients.
2 Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia
Ho B-C, Andreasen NC, et al. Arch Gen Psychiatry. 2011;68(2):128-137.
Abstract: Landmark longitudinal neuroimaging study following first-episode schizophrenia patients for 7–14 years. Greater intensity of antipsychotic treatment was associated with smaller brain tissue volumes — both grey and white matter — independent of illness severity, substance use, and other confounders. Higher cumulative antipsychotic doses correlated with greater brain volume reduction, raising critical questions about informed consent for long-term antipsychotic use.
3 Antipsychotic-induced dopamine supersensitivity psychosis: a comprehensive review
Chouinard G, Chouinard V-A. Curr Pharm Des. 2017;23(32):4730-4744.
Abstract: Comprehensive review establishing that chronic antipsychotic use causes dopamine receptor upregulation and supersensitivity, producing withdrawal psychosis that mimics the original illness. An estimated 39% of psychotic relapses in medication-compliant patients may represent supersensitivity psychosis rather than true disease relapse — a finding with profound implications for how "relapse prevention" data are interpreted.
4 Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis and withdrawal-related relapse
Moncrieff J. Acta Psychiatr Scand. 2006;114(1):3-13.
Abstract: Systematic literature review examining evidence that antipsychotic discontinuation provokes psychosis through pharmacological withdrawal mechanisms rather than disease relapse. Finds strong evidence for withdrawal psychosis following clozapine discontinuation and weaker but consistent evidence for other antipsychotics. Argues that withdrawal studies inflate estimates of antipsychotic efficacy by attributing drug-induced withdrawal psychosis to the underlying illness.
5 Method for tapering antipsychotic treatment that may minimize the risk of relapse
Horowitz MA, et al. Schizophr Bull. 2021;47(4):1116-1129.
Abstract: Demonstrates that dopamine D2 receptor occupancy follows a hyperbolic curve — meaning small dose reductions at low doses produce disproportionately large changes in receptor blockade. Proposes hyperbolic tapering as the pharmacologically rational approach to antipsychotic discontinuation, analogous to the approach now advocated for antidepressants and benzodiazepines. Conventional linear tapers cut too aggressively at lower doses, triggering withdrawal and supersensitivity psychosis.
6 Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis
Carbon M, et al. World Psychiatry. 2018;17(3):330-340.
Abstract: Meta-analysis of randomized controlled trials comparing tardive dyskinesia risk across antipsychotic generations. While second-generation agents showed lower TD risk than first-generation drugs, the absolute risk remained clinically significant. The analysis confirms that no antipsychotic is free of TD risk and that cumulative exposure, age, and prior extrapyramidal symptoms are major risk factors.
7 Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences
Pillinger T, et al. Pharmaceuticals. 2021;14(3):238.
Abstract: Review of metabolic disruption caused by atypical antipsychotics, documenting prevalence of metabolic syndrome in 37–63% of treated patients. Explains molecular mechanisms including histamine H1 blockade, serotonin 5-HT2C antagonism, and direct effects on insulin signaling. Patients face a 3-fold increased risk of severe cardiovascular disease, with metabolic disturbances sometimes preceding weight gain — indicating direct diabetogenic drug effects beyond simple caloric imbalance.
8 Antipsychotic off-label use in the 21st century: an enduring public health concern
Various authors. PMC. 2025.
Abstract: Systematic review documenting that 40–75% of adult antipsychotic prescriptions and 36–93% of pediatric prescriptions are for off-label indications — primarily insomnia, anxiety, ADHD, and agitation. This means millions of people are exposed to risks of tardive dyskinesia, metabolic syndrome, and brain volume loss for conditions these drugs were never approved to treat, raising urgent questions about prescribing standards and informed consent.
Accutane (Isotretinoin): Neuropsychiatric and Systemic Effects
Isotretinoin for severe acne crosses the blood-brain barrier and alters brain metabolism and function. Research documents severe depression, suicidal ideation, cognitive impairment, and lasting neuropsychiatric effects.
Citações Chave:
1 Isotretinoin and neuropsychiatric side effects: continued vigilance needed
Shad MU, Dukkipati S, Karim M, et al. Curr Pharm Des. 2023;29(2):125-142. doi:10.2174/1381612829666230213093751
Abstract: Comprehensive review documenting the spectrum of neuropsychiatric adverse effects associated with isotretinoin, including depression, suicidal ideation, mania, anxiety, and psychosis. The authors emphasize the need for continued clinical vigilance, patient education, and monitoring for neuropsychiatric symptoms throughout treatment. The temporal relationship between isotretinoin administration and psychiatric symptoms warrants ongoing safety surveillance.
2 Functional brain imaging alterations in acne patients treated with isotretinoin
Bremner JD, et al. Am J Psychiatry. 2005;162(5):983-991. doi:10.1176/appi.ajp.162.5.983
Abstract: PET imaging study demonstrating that isotretinoin treatment caused a 21% decrease in brain metabolism in the orbitofrontal cortex — a region critically involved in mood regulation and decision-making — compared to minimal changes in antibiotic-treated controls. This represents direct neuroimaging evidence that isotretinoin alters brain function at the metabolic level, providing a biological mechanism for the neuropsychiatric effects patients report.
3 An analysis of cases of depression, mania, and psychosis reported to the FDA during the use of isotretinoin
Wysowski DK, Pitts M, Beitz J. J Am Acad Dermatol. 2001;45(4):515-519. doi:10.1067/mjd.2001.116215
Abstract: Analysis of FDA adverse event reports from 1982 to 2000 identifying 37 reports of suicide, 110 cases of hospitalized depression or suicidal ideation, and 284 cases with other psychiatric manifestations in isotretinoin-treated patients. Cases demonstrated temporal relationships between drug administration and psychiatric symptoms, with evidence of positive de-challenge and re-challenge responses. Isotretinoin ranked in the top 10 of all drugs in the FDA database for reported depression.
4 Depression and suicidal behavior in acne patients treated with isotretinoin: a retrospective cohort study
Marqueling AL, Zane LT. Arch Dermatol. 2007;143(9):1213-1219.
Abstract: Systematic review of nine studies examining depression and suicidal behavior in isotretinoin-treated patients. Depression rates ranged from 1-11% across studies. The authors noted significant limitations in existing study designs and data collection methods, highlighting the difficulty of detecting serious but relatively rare adverse effects in study populations — a methodological challenge that consistently works in favor of underestimating harm.
5 Isotretinoin use and the risk of inflammatory bowel disease: a case-control study
Crockett SD, Porter CQ, Martin CF, et al. Am J Gastroenterol. 2010;105(9):1986-1993.
Abstract: Case-control study of 8,189 IBD cases and 21,832 controls examining the association between isotretinoin and inflammatory bowel disease. Ulcerative colitis showed a significant association with prior isotretinoin exposure (odds ratio 4.36), suggesting that isotretinoin's effects extend beyond the neuropsychiatric system to include systemic inflammatory injury, particularly in the gastrointestinal tract.
Fluoroquinolones: Multisystem Toxicity and Neurological Damage
Fluoroquinolone antibiotics cause mitochondrial damage at the cellular level, resulting in Fluoroquinolone-Associated Disability (FQAD): a debilitating systemic condition affecting neurological, musculoskeletal, and sensory systems with effects often persisting long after medication discontinuation.
Citações Chave:
2 The safety profile of fluoroquinolones
Jonville-Béra AP, Largeau B, et al. Infectious diseases now. 2025. DOI: 10.1016/j.idnow.2025.105064
Disfunção Mitocondrial: A Base Metabólica da Doença Psiquiátrica e Neurológica
Um corpo crescente de evidências implica a disfunção mitocondrial como um mecanismo fundamental subjacente aos transtornos psiquiátricos e neurológicos. O cérebro consome aproximadamente 20% da energia do corpo apesar de representar apenas 2% da massa corporal — tornando os neurônios particularmente vulneráveis até mesmo a deficiências sutis na produção de energia mitocondrial. A função mitocondrial perturbada leva ao estresse oxidativo, sinalização de cálcio prejudicada, neurinflamação e déficits de energia que impulsionam ou pioram condições que variam de depressão e esquizofrenia a Alzheimer e Parkinson. Este framework tem implicações profundas para entender lesão induzida por medicamento: muitas das drogas documentadas neste site prejudicam diretamente a função mitocondrial.
Citações Chave:
2 Drug-Induced Mitochondrial Toxicity
Hargreaves IP, Al Shahrani M, et al. Drug safety. 2016. DOI: 10.1007/s40264-016-0417-x
3 Drug-induced mitochondrial toxicity
Chan K, Truong D, et al. Expert opinion on drug metabolism & toxicology. 2005. DOI: 10.1517/17425255.1.4.655
4 Psychotropic medications and mitochondrial toxicity
Anglin R, Rosebush P, et al. Nature reviews. Neuroscience. 2012. DOI: 10.1038/nrn3229-c1
11 Drug-induced mitochondrial dysfunction and cardiotoxicity
Varga ZV, Ferdinandy P, et al. American journal of physiology. Heart and circulatory physiology. 2015. DOI: 10.1152/ajpheart.00554.2015
12 Impaired mitochondrial function in psychiatric disorders
Manji H, Kato T, Di Prospero NA, et al. Nature Reviews Neuroscience. 2012;13(5):293-307. DOI: 10.1038/nrn3229
Abstract: Comprehensive review examining the connection between mitochondrial dysfunction and psychiatric illness, including mood disorders and schizophrenia. The authors present evidence that compromised mitochondrial function disrupts synaptic plasticity and cellular resilience — key mechanisms underlying progressive neurological decline. The review identifies mitochondrial pathways as potential therapeutic targets, directly relevant to understanding why drug-induced mitochondrial damage can produce persistent psychiatric and neurological symptoms.
Dieta Cetogênica & Psiquiatria Metabólica: Tratando Doença Psiquiátrica Através do Metabolismo
Se disfunção mitocondrial é uma causa raiz da doença psiquiátrica, então intervenções que restaurem a função mitocondrial devem melhorar os sintomas. A dieta cetogênica — que muda a fonte de combustível do cérebro de glicose para cetonas — está emergindo como exatamente essa intervenção. Originalmente desenvolvida nos anos 1920 para epilepsia, a dieta cetogênica agora está sendo estudada como um tratamento metabólico para esquizofrenia, transtorno bipolar, depressão maior e outras condições psiquiátricas. Os resultados clínicos iniciais são impressionantes, com melhorias tanto na saúde metabólica quanto nos sintomas psiquiátricos que medicações convencionais frequentemente falham em alcançar.
Citações Chave:
1 The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatients
Danan A, Westman EC, Saslow LR, Ede G. Frontiers in Psychiatry. 2022;13:951376. doi:10.3389/fpsyt.2022.951376
Abstract: Retrospective analysis of 31 adults with severe, treatment-refractory mental illness (major depressive disorder, bipolar disorder, schizoaffective disorder) placed on a ketogenic diet (≤20g carbohydrate/day) during psychiatric hospitalization. Hamilton Depression Rating Scale scores improved from 25.4 to 7.7 (p < 0.001) and Montgomery–Åsberg Depression Rating Scale scores from 29.6 to 10.1 (p < 0.001). The most marked improvements were observed in patients with schizoaffective disorder.
2 Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial
Sethi S, et al. Psychiatry Research. 2024;335:115866. doi:10.1016/j.psychres.2024.115866
Abstract: Stanford Medicine pilot trial following 21 adults diagnosed with schizophrenia or bipolar disorder on antipsychotic medications. After four months on a ketogenic diet: 79% of participants showed clinically meaningful psychiatric improvement (≥1 point on Clinical Global Impression scale), 75% were in recovery or a recovered state, and none of the participants met criteria for metabolic syndrome at study conclusion. This is the first U.S.-based clinical trial examining ketogenic dietary intervention for serious mental illness since 1965.
3 The Potential Role of the Ketogenic Diet in Serious Mental Illness: Current Evidence, Safety, and Practical Advice
Norwitz NG, et al. Current Nutrition Reports. 2024;13:330–342. doi:10.1007/s13668-024-00539-1
Abstract: Comprehensive review synthesizing the current evidence for ketogenic diets in serious mental illness, including proposed mechanisms of action: improved mitochondrial function, reduced neuroinflammation, modulation of neurotransmitter systems, and stabilization of neural network activity. Provides practical clinical guidance for implementing ketogenic dietary interventions in psychiatric populations including safety considerations and monitoring protocols.
4 Ketogenic diets in clinical psychology: examining the evidence and implications for practice
Sarnyai Z, et al. Frontiers in Psychology. 2024;15:1468894. doi:10.3389/fpsyg.2024.1468894
Abstract: Review of ketogenic diet evidence across clinical psychology, examining applications in depression, anxiety, bipolar disorder, schizophrenia, and neurodevelopmental conditions. The authors note that psychiatric conditions such as schizophrenia, depression, and bipolar disorder share common mechanistic pathologies including glucose hypometabolism, neurotransmitter imbalances, oxidative stress, and inflammation — all of which the ketogenic diet has been shown to address.
5 The effects of ketogenic metabolic therapy on mental health and metabolic outcomes in schizophrenia and bipolar disorder: a randomized controlled clinical trial protocol
Brinkworth GD, et al. Frontiers in Nutrition. 2024;11:1444483. doi:10.3389/fnut.2024.1444483
Abstract: Protocol for the first randomized controlled trial of ketogenic metabolic therapy in psychiatric illness, enrolling 100 participants with bipolar disorder, schizoaffective disorder, or schizophrenia for a 14-week intervention comparing a ketogenic diet to standard dietary guidelines. This trial represents the next critical step in establishing the evidence base for metabolic approaches to psychiatric treatment.